BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30132370)

  • 21. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trials stopped early for benefit: a systematic review.
    Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
    JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring in clinical trials: benefit or bias?
    Nardini C
    Theor Med Bioeth; 2013 Aug; 34(4):259-74. PubMed ID: 23824468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring a randomized clinical trial for futility: the north-Norwegian lidocaine intervention trial.
    Berntsen RF; Rasmussen K; Bjørnstad JF
    Stat Med; 1991 Mar; 10(3):405-12. PubMed ID: 2028124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis for multinational clinical trials.
    Pinto EM; Willan AR; O'Brien BJ
    Stat Med; 2005 Jul; 24(13):1965-82. PubMed ID: 15803442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating futility of a binary clinical endpoint using early read-outs.
    Van Lancker K; Vandebosch A; Vansteelandt S; De Ridder F
    Stat Med; 2019 Dec; 38(28):5361-5375. PubMed ID: 31631357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The exclusion of women from clinical trials of thrombolytic therapy: implications for developing the thrombolytic predictive instrument database.
    Maynard C; Selker HP; Beshansky JR; Griffith JL; Schmid CH; Califf RM; D'Agostino RB; Laks MM; Lee KL; Wagner GS
    Med Decis Making; 1995; 15(1):38-43. PubMed ID: 7898296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflation of type I error rate in two statistical tests for the detection of publication bias in meta-analyses with binary outcomes.
    Schwarzer G; Antes G; Schumacher M
    Stat Med; 2002 Sep; 21(17):2465-77. PubMed ID: 12205693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative views on setting clinical trial futility criteria.
    Gallo P; Mao L; Shih VH
    J Biopharm Stat; 2014; 24(5):976-93. PubMed ID: 24933121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.